Since 2008, many biotech companies have corporate venture capitalists (CVC) in their boardroom as directors or observers, oftentimes representing more than one strategic investor group. But how does this work when a company signs a partnership with one of their CVC’s parent? Does having boardroom access complicate management of joint research work plans?
This panel pairs three different CVCs with CEOs from their respective portfolios to present the case for having strategic VCs at the table. The participants will discuss how to make an actively managed investment work alongside a research collaboration from the CVC’s parent corporation.
Ability Level: Intermediate
Session ID: 20942